Bullfrog Ai Holdings, Inc. · NASDAQ:BFRG
Bullfrog Ai — Investor Presentation (September 2026)
15 slides from Bullfrog Ai's investor presentation, September 2026
Slide 1: BullFrog AI Holdings Corporate Presentation
BullFrog AI Holdings Nasdaq: BFRG Advancing medicine through artificial intelligence: AI that works for you, not instead of you Corporate Presentation September 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward - looking statements . In addition, from time to time, we or our representatives may make forward - looking statements orally or in writing . We base these forward - looking statements on our expectations and projections about future even
Slide 3: There are BIG problems in the industry
There are BIG problems in the industry • >$200B spent annually on pharma R&D with low return on investment • ~12% success rate for drugs entering Phase 1 - high failure, high cost • ~50% of drugs fail phase 3 • Smaller biotech's lack AI tools to analyze complex biomedical data • Urgent need for purp
Slide 4: Why Invest in BullFrog AI?
Why Invest in BullFrog AI? • Purpose - built proprietary AI platform driving scalable, efficient drug discovery and optimal R&D results • Strategic partnerships fuel unlock of data driven insights and CNS discoveries • Engaging big pharma for commercial deals; secured early commercial validation • E
Slide 5: BullFrog AI: life sciences intelligence
BullFrog AI : life sciences intelligence Proprietary AI and machine learning platform enables precise identification of key targets to significantly advance discovery and clinical programs and access to innovative therapeutics • Decodes biological complexity and improves the success of drug developm
Slide 6: Unique Position in Rapidly Expanding Market
Unique Position in Rapidly Expanding Market BullFrog’s AI design is well - positioned to capitalize across multiple industry verticals to address demand for faster, lower cost drug development Sector Market Growth Velocity Indicator 6
Slide 7: Integrated AI Platform for Pharma R&D
BullFrog AI Innovation: Integrated AI Platform for Pharma R&D Addresses complex cross pharma industry challenges with AI at every step: • bfPREP rapidly cleans, harmonizes, and structures true multimodal data so teams can trust their inputs. • bfLEAP® goes beyond black - box predictions to reveal th
Slide 8: Top 5 Global Pharma Agreement
BullFrog AI’s Top 5 Global Pharma Agreement Achieves top - tier commercial validation of bfLEAP ® technology, positioned for cross sell opportunities of pharma R&D focused intelligence platform Top 5 Global Pharma Strategic Agreement reflects prime commercial validation of differentiated AI solution
Slide 9: Case Study: Powerful Value Proposition
Case Study: Powerful Value Proposition BullFrog AI identified 3x increase in overall survival in patient subgroups through key biomarkers in pancreatic cancer • BullFrog AI solutions identified key biomarker associated with three - fold increase in survival in pancreatic cancer ➢Low blood sugar • St
Slide 10: Case Study: Commercial Access to Proprietary Data
Case Study: Commercial Access to Unique and Proprietary Data for Novel Drug Target Discoveries • LIBD is world’s largest neuropsychiatric brain tissue repository ➢Access to 2,800 brain samples ➢Molecular insights into schizophrenia, bipolar disorder, and major depressive disorder • BullFrog AI’s dat
Slide 11: BullFrog AI's scalable business model
Bullfrog AI’s scalable business model BullFrog’s AI garners strategic partnerships Structure discovery and clinical trial optimization deals with upfront fees, milestones, and royalties ("bio- bucks" model). AI solutions = scalable go to market strategy Leverage internal commercial team and channel
Slide 12: Operational & Strategic Growth Milestones
Operational & Strategic Growth Milestones 2026 shift to commercialization and enterprise adoption, integrated platform and early AI technology validation 1Q26 : Secured commercial agreement 1Q26 : with a top 5 global pharmaceutical 2027 : company to apply bfLEAP ® analytics Expanding commercial agre
Slide 13: Experienced Leadership
Experienced Leadership Vin Singh Josh Blacher Chairman and CEO Chief Financial Officer • Serial entrepreneur with leadership roles in biotech and cell therapy; founder • Veteran CFO with capital markets and operational experience at RNA Disease of Next Healthcare and co - founder of MaxCyte (Nasdaq:
Slide 14: The Dam Has Broken: AI Acquisition by Big Pharma
The Dam Has Broken: AI Acquisition by Big Pharma Big pharma partnering for AI solutions did not satisfy the need to own the AI solutions model, shifting Big pharma to AI acquisitions and investments 14
Slide 15: Why Invest in BullFrog AI?
Why Invest in BullFrog AI? • Purpose - built proprietary AI platform driving scalable, efficient drug discovery and optimal R&D results • Strategic partnerships fuel unlock of data driven insights and CNS discoveries • Engaging big pharma for commercial deals; secured early commercial validation • E
BullFrog AI Holdings — Investor Presentation (September 2026) on 6ix